Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Data validity issues in using claims data.

B L Strom1

  • 1Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA. bstrom@cceb.med.upenn.edu

Pharmacoepidemiology and Drug Safety
|January 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repellent properties of the host compound 4-allylanisole to the southern pine beetle.

Journal of chemical ecology·2013
Same author

Attractant and disruptant semiochemicals for Dendroctonus jeffreyi (Coleoptera: Curculionidae: Scolytinae).

Environmental entomology·2013
Same author

Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury.

International journal of clinical pharmacology and therapeutics·2011
Same author

Diuretic use and the risk of breast cancer.

Journal of human hypertension·2008
Same author

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.

American journal of epidemiology·2007
Same author

Defining optic nerve tortuosity.

AJNR. American journal of neuroradiology·2007
Same journal

Trends in Pharmacist-Prescribed Dispensing Records of HIV Pre-Exposure (2020-2025) and Post-Exposure Prophylaxis (2020-2024) in Brazil: A Time Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

French Consumption of Methylphenidate in Primary Care From 2016 to 2023, Impact of Prescribing Policy Changes-A Time-Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.

Pharmacoepidemiology and drug safety·2026
Same journal

Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap-Weighted Restricted Mean Survival Time Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Association Between EGFR-TKI-Associated Skin Rash and Recorded Mortality in Non-Small Cell Lung Cancer: A Real-World Analysis Accounting for Immortal Time Bias.

Pharmacoepidemiology and drug safety·2026
Same journal

Nationwide Trends in Opioid Consumption in Costa Rica, 2017-2024: Implications for Regulatory Policy and Public Health.

Pharmacoepidemiology and drug safety·2026
See all related articles

Claims data in pharmacoepidemiology can be useful, but diagnosis data validity varies. A study on drug-induced neutropenia provided rich data, while Stevens-Johnson Syndrome yielded less due to diagnostic coding issues.

Area of Science:

  • Pharmacoepidemiology
  • Health Informatics
  • Drug Safety

Background:

  • Claims data are frequently utilized in pharmacoepidemiological research.
  • The accuracy and reliability of diagnosis data within claims databases present significant challenges.
  • Variable data quality can impact the interpretation and utility of study findings.

Purpose of the Study:

  • To overview the use of claims data in pharmacoepidemiology.
  • To examine problems associated with claims data utilization.
  • To focus on the uncertain validity of diagnosis data in pharmacoepidemiological studies.

Main Methods:

  • Comparative analysis of two pharmacoepidemiological studies with similar designs.
  • Study 1: Drug-induced neutropenia (laboratory-driven diagnosis).

Related Experiment Videos

  • Study 2: Stevens-Johnson Syndrome (difficult diagnosis, poorly coded in ICD-9-CM).

    • Main Results:

    • The neutropenia study, with a reliable diagnosis, yielded extensive data on incidence and drug-specific effects, despite revealing issues with chronic/cyclic forms.
    • The Stevens-Johnson Syndrome study, hampered by diagnostic coding limitations, produced significantly less clinical information.
    • Variable data validity critically affects the interpretation of pharmacoepidemiological research.

    Conclusions:

    • The validity of diagnosis data is a crucial determinant of study success in pharmacoepidemiology.
    • Challenges include illnesses not always seeking medical attention, coding system limitations, and uncaptured confounders.
    • Researchers must carefully consider data source limitations when designing and interpreting pharmacoepidemiological studies.